this allowed it to broaden the pipeline beyond those molecules discovered in-house, much as the more traditional pharma companies were doing at this time. By the mid 2000s Amgen was already a giant.

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

"We believe that Amgen is strongly positioned to realize the full potential of Onyx's portfolio and pipeline." Robert Bradway, Amgen chairman and chief executive officer. Chairman and CEO of Onyx ...

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by ...

Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Amgen’s strong commitment to R&D, coupled with its successful integration of strategic acquisitions like Horizon Therapeutics (NASDAQ:HZNP), demonstrates the company’s ability to drive innovation and ...

Amgen’s stock has been rising consistently, with corrections in between due to pipeline setbacks. Amgen’s key medicines, like Evenity and Repatha, newer medicines like Tavneos and Tezspire and ...